NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain

MAPLE GROVE, Minn., Oct. 28 /PRNewswire/ -- NeuroVasx, Inc., a medical device
company that develops technologies for the treatment of hemorrhagic and
ischemic stroke, announced today that the first procedure in Spain utilizing
its cPAX Aneurysm Treatment System was performed in Madrid. cPAX received CE
Mark earlier this year.

Dr. Alfredo Casasco, Interventional Neuroradiology, Department of Endovascular
and Percutaneous Treatment, Clinica Nuestra Senora del Rosario, used 143cm of
cPAX in combination with platinum coils to treat an unruptured aneurysm over
13mm in diameter.

"According to the AngioCalc aneurysm volume calculator, greater than 40%
packing density was achieved with cPAX alone, which we see as a great result,"
said Kathryn Meintsma, Vice President of Marketing, NeuroVasx. "Studies have
indicated that aneurysms packed greater than 24% have a lower incidence of
recanalization."(1,2)

"We are very pleased with the outcome of the first procedure in Spain, which
demonstrates the sophisticated filling capabilities of cPAX in large
aneurysms," said Eric B. Timko, President and Chief Executive Officer,
NeuroVasx. "cPAX was designed to simplify delivery, shorten procedure time and
improve outcomes, and the product's polymer characteristics make it ideally
suited to take on the shape of large aneurysms and attain maximized packing
density. This case marks a significant milestone in our entry into the
European market and we look forward to continuing to introduce cPAX throughout
the EU."

The cPAX System is a minimally invasive device for the embolization of
cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in the
brain. If ruptured, aneurysms can result in massive intracranial bleeding and
often lead to death. cPAX is a polymer strand delivered through a
microcatheter using the same delivery technique as the currently used platinum
coil technology. cPAX was designed to achieve more complete filling of the
aneurysm using fewer devices and provide the physician the ability to detach
the device at any point versus the fixed detachment zone common to platinum
coils. The polymeric material also allows for non-invasive CT and MRI scans
free of metallic artifact for a more accurate patient follow-up assessment.

1. Tamatani S, Ito Y, Abe H, et al: Evaluation of the stability of
aneurysms
after embolization using detachable coils: Correlation between
stability
of aneurysms and embolized volume of aneurysms. AJNR May 2002,
23:762-767.

2. Sluzewski M, Willem JvR, Slob MJ, et al: Relation between aneurysm
volume, packing, and compaction in 145 cerebral aneurysms treated with
coils. Radiology 2004; 231:653-658.

About Cerebral Aneurysms
A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in
the brain which can be caused by a number of factors including congenital
defects, high blood pressure, atherosclerosis, cancer, drug use or head
trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke,
or bleeding on the brain. According to National Institutes of Health,
approximately 40% of these patients do not survive the first 24 hours. The
worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually,
approximately 200,000 of which may be treatable with intracranial surgery or
minimally invasive techniques.

About NeuroVasx, Inc.
NeuroVasx, Inc. (http://www.neurovasx.com/) is a privately held medical device
company located in Maple Grove, MN. The company is dedicated to the
development and commercialization of technologies for the minimally invasive
treatment of hemorrhagic and ischemic stroke. The worldwide market potential
for stroke treatment devices is estimated to be over $3 billion.

Contact: Media Contacts:
Eric B. Timko Jennifer Saunders
President and CEO The Ruth Group
NeuroVasx 646-536-7011
763-315-0013 jsaunders@theruthgroup.com

SOURCE NeuroVasx, Inc.

Eric B. Timko, President and CEO, NeuroVasx, +1-763-315-0013; or Jennifer
Saunders, The Ruth Group, +1-646-536-7011, jsaunders@theruthgroup.com